Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deuremidevir hydrobromide - Vigonvita Life Sciences

Next Previous
X
Search
Drug Profile

Deuremidevir hydrobromide - Vigonvita Life Sciences

Alternative Names: JT-001 - Junshi Biosciences; Mindevir; MINDEWEI®; VV-116

Latest Information Update: 04 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vigonvita Life Sciences
  • Developer Shanghai Junshi Biosciences; Vigonvita Life Sciences
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Organic deuterium compounds; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections
  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 06 May 2024 Vigonvita Life Sciences completes a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) (NCT06328400)
  • 27 Mar 2024 Vigonvita Life Sciences initiates a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) (NCT06328400)
  • 20 Mar 2024 Vigonvita Life Sciences plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) in March 2024 (NCT06328400)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top